uniQure (NASDAQ:QURE) Releases Earnings Results, Misses Expectations By $0.90 EPS

uniQure (NASDAQ:QURE) released its quarterly earnings data on Thursday. The biotechnology company reported ($1.50) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.90), Zacks reports. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%.

uniQure Stock Up 2.6 %

uniQure stock traded up $0.31 during trading hours on Thursday, hitting $11.98. The stock had a trading volume of 738,137 shares, compared to its average volume of 1,002,023. The stock’s 50-day moving average price is $15.19 and its 200-day moving average price is $9.73. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $583.70 million, a P/E ratio of -2.39 and a beta of 0.39.

Analysts Set New Price Targets

A number of equities analysts have recently commented on QURE shares. Cantor Fitzgerald raised their price target on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. Stifel Nicolaus raised their target price on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. The Goldman Sachs Group upped their price target on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. Leerink Partners raised their price objective on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. Finally, StockNews.com raised shares of uniQure to a “sell” rating in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, uniQure presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.74% of the stock is owned by company insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.